W. Robert Fleischmann

Professor

Department of Urologic Surgery & Department of Microbiology

Email: rfleisch@umn.edu
Phone: (612) 626-5034
 

Education

Ph.D., Purdue University, Department of Biological Sciences, 1972

Research Interests

Development of a whole-cell tumor immunotherapy for melanoma; development of a whole-cell tumor immunotherapy for prostate cancer.

Selected Recent Publications

• Fleischmann, W.R. Jr. Interferons in antitumor therapy: Current status and future prospects. Zdravniski Vestnik 63 (Suppl II):15-18.
• Koren, S. and Fleischmann, W.R. Jr. Chronobiology of the interferon system. Zdravniski Vestnik 63 (Suppl II):27-30. 1994. Fleischmann, C.M. and Fleischmann, W.R. Jr. Enhanced in vitro macrophage cytotoxicity against interferon-treated B16 melanoma cells. J. Biol. Reg. Homeost. Agents 9:139-145. 1995.
• Fleischmann, C.M., Stanton, G.J., and Fleischmann, W.R. Jr. Enhanced in vivo sensitivity of in vitro interferon-treated B16 melanoma cells to CD8 cells and activated macrophages. J. Interferon Cytokine Res. 16:805-812. 1996.
• Fleischmann, W.R. Jr. Chapter 43. Viral Genetics. In: S. Baron (ed.). Medical Microbiology, 4th Edition. Galveston: University of Texas Medical Branch, 555-562. 1996.
• Georgiades, J.A. and Fleischmann, W.R. Jr. Oral Application of Cytokines. Biotherapy 8:205-212. 1996.
• Fleischmann, C.M., Wu, T.Y., and Fleischmann, W.R. Jr. B16 melanoma cells exposed in vitro to long-term IFN- treatment (B16 cells) as activators of host cell tumor immunity in mice. J. Interferon Cytokine Res. 17:37-43. 1997.
• Arany, I., Fleischmann, C.M., Tyring, S.K., and Fleischmann, W.R. Jr. Interferon regulates expression of mda-6/WAF1/CIP1 and cyclin-dependent kinases independently from p53 in B16 murine melanoma cells. Biochem. Biophys. Res. Commun. 233:678-680. 1997.
• Arany, I., Fleischmann, C.M., Tyring, S.K., and Fleischmann, W.R. Jr. Lack of mda-6/WAF1/CIP1-mediated inhibition of cyclin-dependent kinases in interferon- resistant murine B16 melanoma cells. Cancer Letters 119:237-240. 1997.
• Fleischmann, W.R. Jr., Masoor, J., Wu, T.Y., and Fleischmann, C.M. Orally administered IFN- acts alone and in synergistic combination with intraperitoneally administered IFN- to exert an antitumor effect against B16 melanoma in mice. J. Interferon Cytokine Res. 18;17-20. 1998.
• Wu, T.Y. and Fleischmann, W.R. Jr. Efficacy of B16 melanoma cells exposed in vitro to long-term IFN- treatment (B16 cells) as a tumor vaccine in mice. J. Interferon Cytokine Res., 18:829-839. 1998.
• Beilharz, M.W. and Fleischmann, W.R. Jr. Guest Editors, Special Topics Issue: Oral Use of Interferons and Cytokines. J. Interferon and Cytokine Res. 19:813-979. 1999.
• Houston, C.W., Dworkin, M., and Fleischmann, W.R. 20th Century Evolution of Microbiological Education. ASM News 61:366-369. 1999
• Beilharz, M.W. and Fleischmann, W.R. Jr. Introduction. J. Interferon Cytokine Res. 19:815. 1999.
• Fleischmann, W.R. Jr. and Koren, S. Systemic effect of orally administered interferons and interleukin-2. J. Interferon Cytokine Res. 19:829-839. 1999.
• Wu, T.Y. and Fleischmann, W.R. Jr. Murine B16 melanoma vaccination-induced tumor immunity: Identification of specific immune cells and functions involved. J. Interferon Cytokine Res., 21:1117-1127. 2001.
• Fleischmann, W.R. Jr. and Wu, T.G. Development of a vaccine against cancers. Medicinski Razgledi 43 (suppl. 5):51-61. 2004.
• Fleischmann, W.R. Jr. and Wu, T.G. Development of an interferon-based cancer vaccine protocol: application to several types of murine cancers. In: D.J.J. Carr (ed.) Interferon Methods and Protocols, Totowa: Humana Press, 151-166. 2005.
• Wu, T.G., Rose, W.A., Albrecht, T.B., Knutson, E.P., Konig, R., Perdigao, J.R., Nguyen, A.P.A., and Fleischmann, W.R. Jr. IFN--induced murine B16 cancer vaccine cells: induction and accumulation of cell-associated IL-15. J. Interferon Cytokine Res. 27: 13-22. 2007.
• Fleischmann, W.R. Jr. and Wu,T.G. Interferons and cancer: From interferon treatment to the use of interferon-treated cancer cells as vaccines. Invited review, in press.
• Fleischmann, W.R. Jr., Koren, S., and Wu, T.G. Oral administration of interferons. Invited review, in press.
• Morais, M.C., K.H.Choi, J.S. Koti, P.R. Chipman, D.L. Anderson and M.G. Rossmann. 2005. Conservation of the capsid structure in tailed dsDNA bacteriophages: the pseudoatomic structure of ø29. Mol. Cell 18:149-159.
• Chemla, Y. R. Aathavan, K. Michaelis, J. Grimes, S. Jardine, P. J. Anderson, D.L. Bustamante, C. 2005. Mechanism of force generation of a viral DNA packaging motor. Cell 122: 683-692.
• Anderson, D. and S. Grimes. 2004. The ø29 DNA packaging motor: seeking the mechanism. In Viral Genome Packaging. C. Catalano, ed., Landes Bioscience, Chapter 7.
• Morais, M. C., S. Kanamaru, M. O. Badasso, J. S. Koti, B. A. L. Owen, C. T. McMurray, D .L.. Anderson, and M. G. Rossmann. 2003. Bacteriophage phi29 scaffolding protein gp7 before and after prohead assembly. Nature Struct. Biol. 10:572-576.
• Wang, H., S. Grimes, D.L. Anderson and P. Serwer. 2003. Terminal protein-induced stretching of bacteriophage ø29 DNA. J. Microscopy 213:172-179.
• Grimes, S., P. J. Jardine, and D. Anderson. 2002. Bacteriophage ø29 DNA packaging. Adv. Virus Res.58:255-294.